Immune checkpoint blockade in renal cell carcinoma

J Surg Oncol. 2021 Mar;123(3):739-750. doi: 10.1002/jso.26339.

Abstract

Immune checkpoint blockade (ICB) is the foundation of current first-line therapies in patients with metastatic renal cell carcinoma (mRCC) with the potential for eliciting long-lasting remissions. With the expanding arsenal of ICB-based therapies, biomarkers of response are urgently needed to guide optimal therapeutic selection. We review the data behind ICB therapy in RCC, emerging biomarkers of response, and the evolving role of surgery in patients with mRCC.

Keywords: biomarkers; cytoreductive nephrectomy; immunotherapy; kidney cancer.

Publication types

  • Review

MeSH terms

  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / immunology
  • Clinical Trials as Topic
  • Humans
  • Immune Checkpoint Inhibitors / immunology
  • Immune Checkpoint Inhibitors / therapeutic use*
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / immunology
  • Randomized Controlled Trials as Topic

Substances

  • Immune Checkpoint Inhibitors